Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group study

Abstract

In January, 1972, the Southwest Oncology Group initiated two randomized studies for patients with advanced breast cancer. The study for patients with prior chemotherapy showed a 33% response rate with adriamycin. The study for patients without previous chemotherapy consisted of three treatment regimens: a weekly repeated combination of cyclophosphamide, methotrexate, 5‐flu‐orouracil, vincristine, and prednisone; these same five drugs given in courses of 5 days repeated every 4 weeks; and adriamycin as a single agent every 3 weeks. For the 283 evaluable patients, the response rates were: weekly combination 63/106 (59%); intermittent combination 39/98 (40%); and adriamycin 31/79 (39%). The median duration of response was 8 months for weekly combination, 10 months for intermittent therapy and only 4 months for adriamycin. Leukopenia was the dose‐limiting toxicity with all three regimens. The weekly combination is the most effective therapy for patients with advanced disease. Extensive trials of combinations that include adriamycin are underway.